🚀 VC round data is live in beta, check it out!
Soleno Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Soleno Therapeutics and similar public comparables like Disc Medicine, Betta Pharmaceuticals, Celldex Therapeutics, Kodiak Sciences and more.
Soleno Therapeutics Overview
About Soleno Therapeutics
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Founded
1999
HQ
Employees
92
Website
Sectors
Financials (LTM)
EV
$2B
Soleno Therapeutics Financials
Soleno Therapeutics reported last 12-month revenue of $272M and EBITDA of $80M.
In the same LTM period, Soleno Therapeutics generated $264M in gross profit, $80M in EBITDA, and $77M in net income.
Revenue (LTM)
Soleno Therapeutics P&L
In the most recent fiscal year, Soleno Therapeutics reported revenue of $190M and EBITDA of $28M.
Soleno Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $272M | XXX | $190M | XXX | XXX | XXX |
| Gross Profit | $264M | XXX | $188M | XXX | XXX | XXX |
| Gross Margin | 97% | XXX | 99% | XXX | XXX | XXX |
| EBITDA | $80M | XXX | $28M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 15% | XXX | XXX | XXX |
| EBIT Margin | 25% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $77M | XXX | $21M | XXX | XXX | XXX |
| Net Margin | 28% | XXX | 11% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Soleno Therapeutics Stock Performance
Soleno Therapeutics has current market cap of $3B, and enterprise value of $2B.
Market Cap Evolution
Soleno Therapeutics' stock price is $52.77.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $3B | 0.4% | XXX | XXX | XXX | $0.40 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSoleno Therapeutics Valuation Multiples
Soleno Therapeutics trades at 9.1x EV/Revenue multiple, and 31.0x EV/EBITDA.
EV / Revenue (LTM)
Soleno Therapeutics Financial Valuation Multiples
As of April 18, 2026, Soleno Therapeutics has market cap of $3B and EV of $2B.
Equity research analysts estimate Soleno Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Soleno Therapeutics has a P/E ratio of 35.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 9.1x | XXX | 13.0x | XXX | XXX | XXX |
| EV/EBITDA | 31.0x | XXX | 87.2x | XXX | XXX | XXX |
| EV/EBIT | 35.7x | XXX | 165.6x | XXX | XXX | XXX |
| EV/Gross Profit | 9.4x | XXX | 13.2x | XXX | XXX | XXX |
| P/E | 35.6x | XXX | 130.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 53.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Soleno Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Soleno Therapeutics Margins & Growth Rates
Soleno Therapeutics' revenue in the last 12 month grew by 97%.
Soleno Therapeutics' revenue per employee in the last FY averaged $2.1M, while opex per employee averaged $1.9M for the same period.
Soleno Therapeutics' rule of 40 is 197% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Soleno Therapeutics' rule of X is 415% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Soleno Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 97% | XXX | 145% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 296% | XXX | 755% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 197% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 415% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $2.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 55% | XXX | 69% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 15% | XXX | 21% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 91% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Soleno Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Soleno Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Disc Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Betta Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Celldex Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Kodiak Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Hisamitsu Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Soleno Therapeutics M&A Activity
Soleno Therapeutics acquired XXX companies to date.
Last acquisition by Soleno Therapeutics was on XXXXXXXX, XXXXX. Soleno Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Soleno Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSoleno Therapeutics Investment Activity
Soleno Therapeutics invested in XXX companies to date.
Soleno Therapeutics made its latest investment on XXXXXXXX, XXXXX. Soleno Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Soleno Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Soleno Therapeutics
| When was Soleno Therapeutics founded? | Soleno Therapeutics was founded in 1999. |
| Where is Soleno Therapeutics headquartered? | Soleno Therapeutics is headquartered in United States. |
| How many employees does Soleno Therapeutics have? | As of today, Soleno Therapeutics has over 92 employees. |
| Who is the CEO of Soleno Therapeutics? | Soleno Therapeutics' CEO is Anish Bhatnagar. |
| Is Soleno Therapeutics publicly listed? | Yes, Soleno Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Soleno Therapeutics? | Soleno Therapeutics trades under SLNO ticker. |
| When did Soleno Therapeutics go public? | Soleno Therapeutics went public in 2014. |
| Who are competitors of Soleno Therapeutics? | Soleno Therapeutics main competitors are Disc Medicine, Betta Pharmaceuticals, Celldex Therapeutics, Kodiak Sciences. |
| What is the current market cap of Soleno Therapeutics? | Soleno Therapeutics' current market cap is $3B. |
| What is the current revenue of Soleno Therapeutics? | Soleno Therapeutics' last 12 months revenue is $272M. |
| What is the current revenue growth of Soleno Therapeutics? | Soleno Therapeutics revenue growth (NTM/LTM) is 97%. |
| What is the current EV/Revenue multiple of Soleno Therapeutics? | Current revenue multiple of Soleno Therapeutics is 9.1x. |
| Is Soleno Therapeutics profitable? | Yes, Soleno Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Soleno Therapeutics? | Soleno Therapeutics' last 12 months EBITDA is $80M. |
| What is Soleno Therapeutics' EBITDA margin? | Soleno Therapeutics' last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Soleno Therapeutics? | Current EBITDA multiple of Soleno Therapeutics is 31.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.